METLIFE INC false 0001099219 0001099219 2024-09-26 2024-09-26 0001099219 us-gaap:CommonStockMember 2024-09-26 2024-09-26 0001099219 us-gaap:SeriesAPreferredStockMember 2024-09-26 2024-09-26 0001099219 us-gaap:SeriesEPreferredStockMember 2024-09-26 2024-09-26 0001099219 us-gaap:SeriesFPreferredStockMember 2024-09-26 2024-09-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 26, 2024

 

 

METLIFE, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

1-15787   13-4075851

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

200 Park Avenue, New York, New York   10166-0188
(Address of Principal Executive Offices)   (Zip Code)

212-578-9500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.01   MET   New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01   MET PRA   New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E   MET PRE   New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F   MET PRF   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.03.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On September 30, 2024, MetLife, Inc. (the “Company”) issued $250,000,000 in additional aggregate principal amount of its 5.300% Senior Notes due 2034 (the “New Senior Notes”). The New Senior Notes were issued as additional notes pursuant to the Senior Indenture, dated as of November 9, 2001 (incorporated by reference to Exhibit 4.1(a) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011), between the Company and The Bank of New York Mellon Trust Company, N.A., (as successor to J.P. Morgan Trust Company, National Association (as successor to Bank One Trust Company, N.A.)), as trustee (the “Trustee”), as supplemented by the Forty-Sixth Supplemental Indenture, dated as of June 5, 2024 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on June 5, 2024), pursuant to which the Company previously issued $500,000,000 aggregate principal amount of its 5.300% Senior Notes due 2034, and the Forty-Seventh Supplemental Indenture, dated as of September 30, 2024 (attached hereto as Exhibit 4.3 and incorporated herein by reference), pursuant to which the New Senior Notes were issued, all of which remain outstanding.

The New Senior Notes were offered and sold pursuant to the shelf registration statement on Form S-3 (File No. 333-268442), filed with the Commission on November 17, 2022, and a prospectus supplement related to the New Senior Notes dated September 26, 2024 (filed with the Commission pursuant to Rule 424(b)(2) under the Securities Act of 1933).

 

Item 8.01.

Other Events

On September 26, 2024, the Company entered into (i) an underwriting agreement (attached hereto as Exhibit 1.1 and incorporated herein by reference) and (ii) a pricing agreement (attached hereto as Exhibit 1.2 and incorporated herein by reference) (the “Pricing Agreement”) relating to the sale of the New Senior Notes, each among the Company and Morgan Stanley & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule I to the Pricing Agreement.

A copy of the opinion letter of Willkie Farr & Gallagher LLP, relating to the validity of the New Senior Notes is attached as Exhibit 5.1 hereto.

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibit
No.
   Description of Exhibit
 1.1    Underwriting Agreement, dated as of September 26, 2024, among the Company and Morgan Stanley & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule I to the Pricing Agreement.
 1.2    Pricing Agreement, dated September 26, 2024, among the Company and Morgan Stanley & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein.
 4.1    Senior Indenture, dated as of November 9, 2001, between the Company and the Trustee (incorporated by reference to Exhibit 4.1(a) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011).
 4.2    Forty-Sixth Supplemental Indenture, dated as of June 5, 2024, between the Company and the Trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 5, 2024).
 4.3    Forty-Seventh Supplemental Indenture, dated as of September 30, 2024, between the Company and the Trustee.
 4.4    Form of Senior Note (included as Exhibit A to Exhibit 4.3 above).
 5.1    Opinion Letter of Willkie Farr & Gallagher LLP relating to the validity of the New Senior Notes.
23.1    Consent of Willkie Farr & Gallagher LLP (included in Exhibit 5.1 above).
101    Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).
104    Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

 

- 2 -


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    METLIFE, INC.
Date: September 30, 2024     By:  

/s/ Tamara L. Schock

    Name:   Tamara L. Schock
    Title:   Executive Vice President and Chief Accounting Officer

 

- 3 -